Skip to content
The Policy VaultThe Policy Vault

Brukinsa (zanubrutinib) — Medica

Marginal zone lymphoma

Initial criteria

  • Patient is age ≥ 18 years
  • Patient has tried at least one systemic regimen

Approval duration

1 year